Mikhail Blagosklonny: различия между версиями

Mikhail Blagosklonny (править)

591 байт убрано , 22 октябрь

3741

правка

@@ Строка 10: / Строка 10: @@
 ==Rapamycin and aging==
-Blagosklonny has formulated a hypothesis about the possible role of [[TOR signaling]] in aging and cancer and proposed using [[rapamycin]], a popular cancer drug as a possible treatment for life extension.<ref>{{cite journal |first=David|last=Stipp|title=A New Path to Longevity |journal=[[Scientific American]] |date=2011 |volume=306|issue=1|doi=10.1038/scientificamerican0112-32 |pages=32–39|pmid=22279832|bibcode=2011SciAm.306f..32S}}</ref> He advocates for rapamycin use in longevity research.<ref>{{cite news |url=https://www.bloomberg.com/news/features/2015-02-12/does-a-real-anti-aging-pill-already-exist-|title = Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015|newspaper = Bloomberg.com|date = 12 February 2015|accessdate = November 20, 2016}}</ref>
+Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[4] He advocates for rapamycin use in longevity research.
 == Editorial activities==